Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor

详细信息    查看全文

• 作者：Shaimaa Makled ; Noha Nafee ; ^{n.nafe3@gmail.com} ; ^{noha.nafaee@alexu.edu.eg} ; ^{nnadel_pharm@yahoo.com} ; Nabila Boraie
• 关键词：Pulmonary hypertension ; Phosphodiesterase-5-inhibitors ; Sildenafil citrate ; Solid lipid nanoparticles ; Nebulization ; Mucus interaction
• 刊名：International Journal of Pharmaceutics
• 出版年：2017
• 出版时间：30 January 2017
• 年：2017
• 卷：517
• 期：1-2
• 页码：312-321
• 全文大小：1669 K
• 卷排序：517

文摘

Phosphodiesterase type 5 (PDE-5) inhibitors – among which sildenafil citrate (SC) – play a primary role in the treatment of pulmonary hypertension (PH). Yet, SC can be only administered orally or parenterally with lot of risks. Targeted delivery of SC to the lungs via inhalation/nebulization is mandatory. In this study, solid lipid nanoparticles (SLNs) loaded with SC were prepared and characterized in terms of colloidal, morphological and thermal properties. The amount of drug loaded and its release behavior were estimated as a function of formulation variables. The potential of lipid nanocarriers to retain their properties following nebulization and autoclaving was investigated. In addition, toxicity aspects of plain and loaded SLNs on A549 cells were studied with respect to concentration. Spherical SLNs in the size range (100–250 nm) were obtained. Particles ensured high encapsulation efficiency (88–100%) and sustained release of the payload over 24 h. Cell-based viability experiments revealed a concentration-dependant toxicity for both plain and loaded SLNs recording an IC50 of 516 and 384 μg/mL, respectively. Nebulization with jet nebulizer and sterilization via autoclaving affected neither the colloidal stability of SLNs nor the drug entrapment, proving their potential as pulmonary delivery system. Interaction of SLNs with mucin was a function of the emulsifier coating layer. Results yet seeking clinical evidence – might give promises of new therapy for PH of higher safety, better performance and higher patient compliance.